Cancer drugs in the United States: Justum Pretium--the just price.
作者信息
Kantarjian Hagop M, Fojo Tito, Mathisen Michael, Zwelling Leonard A
机构信息
Hagop M. Kantarjian, Michael Mathisen, and Leonard A. Zwelling, MD Anderson Cancer Center, Houston, TX; and Tito Fojo, National Cancer Institute, National Institutes of Health, Bethesda, MD.
出版信息
J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. Epub 2013 May 6.
Abstract
摘要
相似文献
1
Cancer drugs in the United States: Justum Pretium--the just price.美国的抗癌药物：公平价格——合理的价格。
J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. Epub 2013 May 6.
2
Challenging the soaring price of cancer medicines: a call for equity and transparency.挑战抗癌药物的高昂价格：呼吁公平与透明。
Ann Oncol. 2016 Sep;27(9):1812-3. doi: 10.1093/annonc/mdw195. Epub 2016 May 6.
3
Cancer drug prices and the free-market forces.抗癌药物价格与自由市场力量
Cancer. 2013 Nov 15;119(22):3903-5. doi: 10.1002/cncr.28330. Epub 2013 Aug 26.
4
Market spiral pricing of cancer drugs.癌症药物的市场螺旋式定价。
Cancer. 2013 Nov 15;119(22):3900-2. doi: 10.1002/cncr.28321. Epub 2013 Sep 3.
5
The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.抗癌药物的合理价格与癌症治疗成本的不断上升：肿瘤学家需要成为解决方案的一部分。
J Clin Oncol. 2013 Oct 1;31(28):3487-9. doi: 10.1200/JCO.2013.50.3466. Epub 2013 Sep 3.
6
Expensive cancer therapies: unintended effects.昂贵的癌症治疗方法：意外的影响。
J Natl Cancer Inst. 2015 Jan 6;107(1):497. doi: 10.1093/jnci/dju497. Print 2015 Jan.
7
Can treatment costs be tamed?治疗成本能得到控制吗？
Science. 2011 Mar 25;331(6024):1545-7. doi: 10.1126/science.331.6024.1545.
8
US hospitals object to changes in Genentech drug distribution.美国医院反对基因泰克公司药品分销的变革。
Lancet Oncol. 2014 Dec;15(13):e591. doi: 10.1016/S1470-2045(14)71040-X. Epub 2014 Nov 7.
9
Cancer Drugs: An International Comparison of Postlicensing Price Inflation.癌症药物：上市后价格通胀的国际比较
J Oncol Pract. 2017 Jun;13(6):e538-e542. doi: 10.1200/JOP.2016.014431. Epub 2017 Feb 7.
10
Soaring price of cancer drugs leads plans to new approaches.抗癌药物价格飙升促使人们计划采用新方法。
Manag Care. 2007 Aug;16(8):12-3.
引用本文的文献
1
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.在ALK阳性非小细胞肺癌患者中一线与二线使用布加替尼后再使用劳拉替尼的成本效益
Front Public Health. 2024 Feb 15;12:1213318. doi: 10.3389/fpubh.2024.1213318. eCollection 2024.
2
How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data.国家医保覆盖政策如何改变晚期肝细胞癌成年患者使用仑伐替尼的情况：一项基于真实世界大数据的回顾性队列分析。
Int J Equity Health. 2023 Dec 11;22(1):256. doi: 10.1186/s12939-023-02052-9.
3
The role of gut microbiota and metabolites in cancer chemotherapy.肠道微生物群和代谢物在癌症化疗中的作用。
J Adv Res. 2024 Oct;64:223-235. doi: 10.1016/j.jare.2023.11.027. Epub 2023 Nov 26.
4
Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers.PD-1/PD-L1抑制剂在食管癌和胃肠道癌治疗中的价值评估
Front Pharmacol. 2023 Apr 21;14:1106961. doi: 10.3389/fphar.2023.1106961. eCollection 2023.
5
The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study.中国 44 家医院 TKI/抑酸剂伴随使用的现状：一项横断面描述性研究。
Medicine (Baltimore). 2022 Nov 18;101(46):e31770. doi: 10.1097/MD.0000000000031770.
6
Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.中国南京谈判靶向抗癌药物可及性的变化趋势：一项中断时间序列分析。
Front Public Health. 2022 Jul 22;10:942638. doi: 10.3389/fpubh.2022.942638. eCollection 2022.
7
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.二十年回顾：实体瘤疗效评估标准（RECIST）作为实体瘤反应生物标志物——欧洲癌症研究与治疗组织（EORTC）影像组与欧洲肿瘤内科学会（ESOI）联合论文
Front Oncol. 2022 Jan 10;11:800547. doi: 10.3389/fonc.2021.800547. eCollection 2021.
8
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades.过去二十年美国食品药品监督管理局批准的蛋白激酶抑制剂研发中的创新与专利趋势
Pharmaceuticals (Basel). 2021 Jul 22;14(8):710. doi: 10.3390/ph14080710.
9
Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study.国家医保覆盖政策对中国创新抗癌药物的利用和可及性的影响：一项中断时间序列研究。
Front Public Health. 2021 Aug 6;9:714127. doi: 10.3389/fpubh.2021.714127. eCollection 2021.
10
Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease.转移性疾病放疗联合免疫治疗临床试验的考量因素
Semin Radiat Oncol. 2021 Jul;31(3):217-226. doi: 10.1016/j.semradonc.2021.02.005.
本文引用的文献
1
Survival trends among patients with advanced renal cell carcinoma in the United States.美国晚期肾细胞癌患者的生存趋势。
Urol Int. 2015;94(2):133-6. doi: 10.1159/000364951. Epub 2014 Aug 19.
2
Cost control in a parallel universe: Medicare spending in the United States and Canada.平行世界中的成本控制：美国和加拿大的医疗保险支出
Arch Intern Med. 2012 Dec 10;172(22):1764-6. doi: 10.1001/2013.jamainternmed.272.
3
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.心电图（ECG）在抗肿瘤药物 I 期临床试验中的应用：MD 安德森癌症中心 8518 例心电图的经验。
Ann Oncol. 2012 Nov;23(11):2960-2963. doi: 10.1093/annonc/mds130. Epub 2012 Jun 27.
4
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代慢性髓性白血病发病率的增长和平台期发病率的估计。
Cancer. 2012 Jun 15;118(12):3123-7. doi: 10.1002/cncr.26679. Epub 2012 Jan 31.
5
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).达沙替尼或伊马替尼治疗新诊断的慢性期慢性髓性白血病：一项随机 3 期试验（DASISION）的 2 年随访结果。
Blood. 2012 Feb 2;119(5):1123-9. doi: 10.1182/blood-2011-08-376087. Epub 2011 Dec 9.
6
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.
7
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.依匹单抗联合达卡巴嗪治疗未经治疗的转移性黑色素瘤。
N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.
8
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.BRAF V600E 突变型黑色素瘤患者采用威罗菲尼治疗后生存改善。
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
9
Bending the cost curve in cancer care.控制癌症治疗成本
N Engl J Med. 2011 May 26;364(21):2060-5. doi: 10.1056/NEJMsb1013826.
10
A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine.美国国家癌症临床试验网络：来自美国医学研究所的建议。
Am J Ther. 2011 Sep;18(5):382-91. doi: 10.1097/MJT.0b013e3181ff7e23.
Zotero 插件